After surgery and removal of the tumor, massively parallel sequencing (via whole-exome and RNA sequencing) can be used to identify the mutational spectrum of the patient's tumor. A pool of potential mutated peptide epitopes deduced from the sequencing data can then be used directly, or pre ...